Press Detail

/
PRESS RELEASE

Biotest enters into an exclusive cooperation agreement with Kedrion Biopharma for the distribution of Bivigam^® in the U.S.

- Kedrion Biopharma takes over the distribution of Bivigam^® in the U.S.

- U.S. production utilization will increase in 2016

- Earnings increase by USD 4-5 million in the first year

Dreieich, January 19, 2016. Biotest Pharmaceuticals Corporation, Boca Raton, Florida, USA (BPC), a subsidiary of Biotest AG, and Kedrion Biopharma Inc., Fort Lee, New Jersey, USA (Kedrion Biopharma), a subsidiary of Kedrion SpA, have entered into an exclusive, seven year cooperation agreement (including a two years wind-down period) for the distribution of Bivigam^® in the U.S.. Bivigam^® is a polyvalent immunoglobulin, which has been manufactured and distributed in the USA since February 2013 and has been well accepted by patients and health care practitioners.

Kedrion Biopharma is an established manufacturer and distributor in the U.S. market with a well-developed sales and distribution network and is therefore an optimal partner for Biotest. Starting immediately, Kedrion Biopharma will take over exclusive distribution of Bivigam^® in the U.S. from BPC. The term of this agreement shall continue until December 31, 2022.

In its first year, Kedrion Biopharma plans to sell a quantity of Bivigam^® that will represent over 30% growth in units over the sales that Bivigam^® achieved in calendar year 2015. The plan is to continuously increase this sales volume in the coming years. This will significantly improve the utilization of BPC’s production facility, and idle capacity costs, which have been incurred in the past, will be substantially reduced. The higher production volume will enable the optimization of the entire production process in order to further enhance profitability in the future. BPC will be reducing its own distribution structure for Bivigam^®. In its first year, an earnings increase in the range of USD 4-5 million is expected.

About Kedrion Biopharma

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, immune system deficiencies and Rh sensitization. Kedrion Biopharma Inc, the US subsidiary of Kedrion Biopharma, is headquartered in Fort Lee, New Jersey. Kedrion Biopharma launched US operations in 2011, but the company’s international roots stretch back several decades in the production of blood and plasma-derived products. Kedrion Biopharma places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves.
Additional information about Kedrion Biopharma can be found at www.kedrion.com and www.kedrion.us.

About Biotest
Biotest AG is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition Biotest develops monoclonal antibodies in the indication cancer of plasma cells and systemic lupus erythematosus (SLE), which are produced by recombinant technologies. Biotest has more than 2,200 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
email: investor_relations@biotest.de

Securities’ ID No., ISIN ordinary shares: 522720, DE0005227201
Securities’ ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.